Capsida Biotherapeutics yesterday revealed US pharma major AbbVie has exercised an option for the first neurodegenerative ...

Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies ...

QurAlis Corporation ("QurAlis"), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of ...

Parlay Finance, a SaaS-based Loan Intelligence System (LIS) for credit unions and community banks issuing SBA and small business loans, today announced the availability of its white paper, ...

Capsida Biotherapeutics ("Capsida") today announced that AbbVie has exercised an option for the first neurodegenerative ...

Shares of AbbVie Inc. ABBV slid 0.44% to $179.20 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.07% to ...

With its shares offering a total return of nearly 49% over the last three years, trumping the market's return of 33%, AbbVie (NYSE: ABBV) is a powerhouse big pharma that has a lot of upside to ...

In addition to its wholly owned programs, the Company has validating partnerships with AbbVie, Lilly, and CRISPR Therapeutics. Capsida was founded in 2019 by lead investors Versant Ventures and ...

On December 18, a recent SEC filing unveiled that Kevin K Buckbee, SVP at AbbVie ABBV made an insider sell. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on ...

In addition to its wholly owned programs, the Company has validating partnerships with AbbVie, Lilly, and CRISPR Therapeutics. Capsida was founded in 2019 by lead investors Versant Ventures and ...